Blue­Rock, Bay­er's stem cell group, de­tails glimpses of ef­fi­ca­cy in Parkin­son's dis­ease ther­a­py

A treat­ment that aims to re­store the dam­aged and dy­ing brain cells that cause un­con­trol­lable move­ments in Parkin­son’s dis­ease is show­ing promis­ing, al­beit ear­ly, signs of be­ing safe and ef­fec­tive.

Blue­Rock Ther­a­peu­tics, Bay­er’s stem cell ther­a­py sub­sidiary, on Mon­day re­vealed the first de­tailed look at the re­sults from a Phase I tri­al of be­m­dane­pro­cel, a ther­a­py made from lab-grown neu­rons sur­gi­cal­ly im­plant­ed in the brains of 12 pa­tients with Parkin­son’s.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER